Research ArticleOriginal Article
Open Access

Are proton pump inhibitors among the risk factors for acute coronary syndrome?

A multi-centric case-control study between patients attending governmental hospitals in western Saudi Arabia

Banan M. Alamoudi, Nahla K. Ibrahim and Bakr B. M. Kalo
Saudi Medical Journal November 2019, 40 (11) 1098-1104; DOI: https://doi.org/10.15537/smj.2019.11.24602

References

  1. ↵
    1. Khaled S,
    2. Matahen R
    (2018) Cardiovascular risk factors profile in patients with acute coronary syndrome with particular reference to left ventricular ejection fraction. Indian Heart J 70:45–49.
    OpenUrl
  2. ↵
    1. Ibrahim NK,
    2. Mahnashi M,
    3. Al-Dhaheri A,
    4. Al-Zahrani B,
    5. Al-Wadie E,
    6. Aljabri M,
    7. et al.
    (2014) Risk factors of coronary heart disease among medical students in King Abdulaziz University, Jeddah, Saudi Arabia. BMC Public Health 14:411.
    OpenUrl
  3. ↵
    1. Ahmed AM,
    2. Hersi A,
    3. Mashhoud W,
    4. Arafah MR,
    5. Abreu PC,
    6. Al Rowaily MA,
    7. et al.
    (2017) Cardiovascular risk factors burden in Saudi Arabia:The Africa Middle East Cardiovascular Epidemiological (ACE) study. J Saudi Heart Assoc 29:235–243.
    OpenUrl
  4. ↵
    1. Al-Saif SM,
    2. Alhabib KF,
    3. Ullah A,
    4. Hersi A,
    5. Alfaleh H,
    6. Alnemer K,
    7. et al.
    (2012) Age and its relationship to acute coronary syndromes in the Saudi Project for Assessment of Coronary Events (SPACE) registry:The SPACE age study. J Saudi Heart Assoc 24:9–16.
    OpenUrlCrossRefPubMed
  5. ↵
    1. El-Menyar A,
    2. Zubaid M,
    3. Shehab A,
    4. Bulbanat B,
    5. Albustani N,
    6. Alenezi F,
    7. et al.
    (2011) Prevalence and impact of cardiovascular risk factors among patients presenting with acute coronary syndrome in the middle East. Clin Cardiol 34:51–58.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Tzoulaki I,
    2. Elliott P,
    3. Kontis V,
    4. Ezzati M
    (2016) Worldwide exposures to cardiovascular risk factors and associated health effects:current knowledge and data gaps. Circulation 133:2314–2333.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Pello Lázaro AM,
    2. Cristóbal C,
    3. Franco-Peláez JA,
    4. Tarín N,
    5. Aceña Á,
    6. Carda R,
    7. et al.
    (2017) Use of proton-pump inhibitors predicts heart failure and death in patients with coronary artery disease. PloS One 12:e0169826.
    OpenUrl
  8. ↵
    1. Savarino V,
    2. Dulbecco P,
    3. de Bortoli N,
    4. Ottonello A,
    5. Savarino E
    (2017) The appropriate use of proton pump inhibitors (PPIs):need for a reappraisal. European Journal of Internal Medicine 37:19–24.
    OpenUrl
  9. ↵
    1. Gray SL,
    2. LaCroix AZ,
    3. Larson J,
    4. Robbins J,
    5. Cauley JA,
    6. Manson JE,
    7. et al.
    (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women:results from the Women's Health Initiative. Arch Intern Med 170:765–771.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Hoorn EJ,
    2. van der Hoek J,
    3. de Man RA,
    4. Kuipers EJ,
    5. Bolwerk C,
    6. Zietse R
    (2010) A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 56:112–116.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Charlot M,
    2. Ahlehoff O,
    3. Norgaard ML,
    4. Jorgensen CH,
    5. Sorensen R,
    6. Abildstrom SZ,
    7. et al.
    (2010) Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use:a nationwide cohort study. Ann Intern Med 153:378–386.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Ho PM,
    2. Maddox TM,
    3. Wang L,
    4. Fihn SD,
    5. Jesse RL,
    6. Peterson ED,
    7. et al.
    (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301:937–944.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Gerson LB
    (2013) Proton pump inhibitors and potential interactions with clopidogrel:an update. Curr Gastroenterol Rep 15:329.
    OpenUrl
  14. ↵
    1. Goodman SG,
    2. Clare R,
    3. Pieper KS,
    4. Nicolau JC,
    5. Storey RF,
    6. Cantor WJ,
    7. et al.
    (2012) Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor:insights from the platelet inhibition and patient outcomes trial. Circulation 125:978–986.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Charlot M,
    2. Grove EL,
    3. Hansen PR,
    4. Olesen JB,
    5. Ahlehoff O,
    6. Selmer C,
    7. et al.
    (2011) Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction:nationwide propensity score matched study. BMJ 342:d2690.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Juurlink DN,
    2. Gomes T,
    3. Ko DT,
    4. Szmitko PE,
    5. Austin PC,
    6. Tu JV,
    7. et al.
    (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180:713–718.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Ghebremariam YT,
    2. LePendu P,
    3. Lee JC,
    4. Erlanson DA,
    5. Slaviero A,
    6. Shah NH,
    7. et al.
    (2013) Unexpected effect of proton pump inhibitors:elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 128:845–853.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Ari H,
    2. Ari S,
    3. Erdogan E,
    4. Tiryakioglu O,
    5. Ustundag Y,
    6. Huysal K,
    7. et al.
    (2010) A novel predictor of restenosis and adverse cardiac events:asymmetric dimethylarginine. Heart Vessels 25:19–26.
    OpenUrlCrossRefPubMedWeb of Science
    1. Boger RH,
    2. Sullivan LM,
    3. Schwedhelm E,
    4. Wang TJ,
    5. Maas R,
    6. Benjamin EJ,
    7. et al.
    (2009) Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119:1592–1600.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Lu TM,
    2. Chung MY,
    3. Lin MW,
    4. Hsu CP,
    5. Lin SJ
    (2011) Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 153:135–140.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Dean AG,
    2. Sullivan KM,
    3. Soe MM
    OpenEpi:Open source epidemiologic statistics for public health, cited 2015, Available from: www.OpenEpi.com.
  22. ↵
    1. Mayet A
    (2007) Improper use of antisecretory drugs in a tertiary care teaching hospital:an observational study. Saudi Journal of Gastroenterology 13:124–128.
    OpenUrl
  23. ↵
    1. Gupta E,
    2. Bansal D,
    3. Sotos J,
    4. Olden K
    (2010) Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci 55:1964–1968.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Bauman A,
    2. Ainsworth BE,
    3. Sallis JF,
    4. Hagströmer M,
    5. Craig CL,
    6. Bull FC,
    7. et al.
    (2011) The descriptive epidemiology of sitting:a 20-country comparison using the International Physical Activity Questionnaire (IPAQ). American Journal of Preventive Medicine 41:228–235.
    OpenUrlCrossRefPubMed
  25. ↵
    1. James PA,
    2. Oparil S,
    3. Carter BL,
    4. Cushman WC,
    5. Dennison-Himmelfarb C,
    6. Handler J,
    7. et al.
    (2014) 2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA 311:507–520.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. American Diabetes Association. Diagnosis and classification of diabetes mellitus
    (2010) Diabetes Care 33(Supplement 1):S62–S69.
    OpenUrlFREE Full Text
  27. ↵
    1. Wang Y,
    2. Lim Hn Caballero B,
    3. Use and interpretation of anthropometry
    (2012) Modern nutrition in health and disease (Wolters Kluwer Health Adis (ESP), South Holland (Netherlands)), 11th ed, pp 649–659.
  28. ↵
    1. Stone NJ,
    2. Robinson JG,
    3. Lichtenstein AH,
    4. Bairey Merz CN,
    5. Blum CB,
    6. Eckel RH,
    7. et al.
    (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63(25 Pt B):2889–2934.
    OpenUrlFREE Full Text
  29. ↵
    1. Kastorini CM,
    2. Georgousopoulou E,
    3. Vemmos KN,
    4. Nikolaou V,
    5. Kantas D,
    6. Milionis HJ,
    7. et al.
    (2013) Comparative analysis of cardiovascular disease risk factors influencing nonfatal acute coronary syndrome and ischemic stroke. Am J Cardiol 112:349–354.
    OpenUrl
  30. ↵
    1. Panduranga P,
    2. Sulaiman K,
    3. Al-Zakwani I,
    4. Abdelrahman S
    (2010) Acute coronary syndrome in young adults from Oman:results from the gulf registry of acute coronary events. Heart Views 11:93–98.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Al Suwaidi J,
    2. Zubaid M,
    3. El-Menyar AA,
    4. Singh R,
    5. Asaad N,
    6. Sulaiman K,
    7. et al.
    (2012) Prevalence and outcome of cigarette and waterpipe smoking among patients with acute coronary syndrome in six Middle-Eastern countries. Eur J Prev Cardiol 19:118–125.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Simon T,
    2. Steg PG,
    3. Gilard M,
    4. Blanchard D,
    5. Bonello L,
    6. Hanssen M,
    7. et al.
    (2011) Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction:results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 123:474–482.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Shih CJ,
    2. Chen YT,
    3. Ou SM,
    4. Li SY,
    5. Chen TJ,
    6. Wang SJ
    (2014) Proton pump inhibitor use represents an independent risk factor for myocardial infarction. International Journal of Cardiology 177:292–27.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Shah NH,
    2. LePendu P,
    3. Bauer-Mehren A,
    4. Ghebremariam YT,
    5. Iyer SV,
    6. Marcus J,
    7. et al.
    (2015) Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PloS One 10:e0124653.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Bhurke SM,
    2. Martin BC,
    3. Li C,
    4. Franks AM,
    5. Bursac Z,
    6. Said Q
    (2012) Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy 32:809–818.
    OpenUrlCrossRefPubMed
    1. Huang B,
    2. Huang Y,
    3. Li Y,
    4. Yao H,
    5. Jing X,
    6. Huang H,
    7. et al.
    (2012) Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease:a systematic review and meta-analysis. Arch Med Res 43:212–224.
    OpenUrlCrossRefPubMed
    1. Kimura T,
    2. Morimoto T,
    3. Furukawa Y,
    4. Nakagawa Y,
    5. Kadota K,
    6. Iwabuchi M,
    7. et al.
    (2011) Association of the use of proton pump inhibitors with adverse cardiovascular and bleeding outcomes after percutaneous coronary intervention in the Japanese real world clinical practice. Cardiovasc Interv Ther 26:222–233.
    OpenUrl
    1. Ortolani P,
    2. Marino M,
    3. Marzocchi A,
    4. De Palma R,
    5. Branzi A
    (2012) One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors:results from a regional cohort study. J Cardiovasc Med (Hagerstown) 13:783–789.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Tsai YW,
    2. Wen YW,
    3. Huang WF,
    4. Chen PF,
    5. Kuo KN,
    6. Hsiao FY
    (2011) Cardiovascular and gastrointestinal events of three antiplatelet therapies:clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol 46:39–45.
    OpenUrlPubMed
  40. ↵
    1. Yusuf S,
    2. Hawken S,
    3. Ounpuu S,
    4. Dans T,
    5. Avezum A,
    6. Lanas F,
    7. et al.
    (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart study):case-control study. Lancet 364:937–952.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. World Health Organization
    Global Physical Activity Surveillance, GPAQ show cards 2015, Available from: http://www.who.int/chp/steps/GPAQ/en/.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section